How can we better predict treatment outcomes in classical Hodgkin's lymphoma?

Abstract

“ The results indicate that response-adapted therapy based on PET-2 results guarantees a PFS, in PET-2 positive patients and in the overall cohort, higher than PFS of historical controls treated with ABVD. ”